Search Results
Jul 14, 2026, 15:12 ET American Tinnitus Association Announces Largest Research Investment in Its History
Clayton, PhD, Massachusetts Eye and Ear/Harvard Medical School, for Restoring Inhibitory Brain Circuits to Reverse Tinnitus ($220,000)William Sedley, MBBS, PhD, Newcastle University, UK, for Objective Diagnosis and Tinnitus Subtyping ($199,409)Philippe Fournier, PhD, Université
More news about: American Tinnitus Association
Jul 14, 2026, 11:19 ET Diranersen Results at AAIC Provide First Evidence That Targeting Tau May Slow Cognitive Decline, Signaling Momentum Toward Addressing the Full Pathobiology of Alzheimer's
from a randomized trial to show a tau-targeting drug producing both a robust biomarker effect and a signal of clinical benefit," said Laura Nisenbaum, PhD, Interim Chief Science Officer at the Alzheimer's Drug Discovery Foundation (ADDF). "Tau is one of the two defining pathologies of Alzheimer's disease
More news about: Alzheimer's Drug Discovery Foundation
Jul 14, 2026, 11:00 ET ABMS Announces New Board of Directors Chair-Elect and Members
Michael R. Nelson, MD, PhD Named Chair-ElectCHICAGO, July 14, 2026 /PRNewswire/ -- The American Board of Medical Specialties (ABMS), the leading not-for-profit organization overseeing the certification
More news about: American Board of Medical Specialties
Jul 14, 2026, 10:00 ET Auxilium Health Closes Oversubscribed $3.4 Million Seed Round to Advance Its Aer™ Biomaterial Platform
the mission."Last year, the question was whether the science was real. This year, it's how fast we can get it to patients," said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. "We're grateful to our investors and partners who believe in the science and the team behind what we're building.
More news about: Auxilium Health
Jul 14, 2026, 10:00 ET Lupus Foundation of America Funds Innovative Research Studying CAR-Treg Therapy for Children with Lupus
achieve disease remission – both at a critical time in their lives and to support a future without the burdens of a chronic illness," shared Joy Buie, PhD, MSCR, RN, Vice President of Research, Lupus Foundation of America.Learn more about the 2026 pediatric grant recipient and her study
More news about: Lupus Foundation of America, Inc.
Jul 14, 2026, 09:56 ET Kedrion Biopharma Advances Rare Disease Scientific Evidence Generation at ISTH 2026
gender."Assessing the time from symptom onset to diagnosis of PLGD-1 allows us to better understand the patient journey," said Karen Thibaudeau, PhD, Global Medical Therapeutic Area Lead for Plasminogen Deficiency at Kedrion. "Patients with PLGD-1 often face a lengthy period between their first symptoms
More news about: Kedrion Biopharma
Jul 14, 2026, 09:00 ET Nucs AI and Segmed Partner to Build the Data Foundation for Precision Oncology
imaging modalities, and clinical applications."We have spent years building the data foundation that precision oncology requires," said Jie Wu, PhD, Co-founder & Chief Data Officer, Segmed. "The next step has always been finding partners who know how to use it. Nucs AI is asking precisely the
More news about: Nucs AI
Jul 14, 2026, 08:50 ET Beyond Finance Launches Industry's First Free Clinically-Informed Financial Wellness Framework to Help Americans Create Lasting Financial Change
Developed by Dr. Erika Rasure, PhD, CFT, the Financial Wellness RESET Framework, Assessment, and Curriculum make professional-grade financial wellness tools freely available to help Americans move beyond survival mode and build healthier financial lives amid record household debt
More news about: Beyond Finance
Jul 14, 2026, 08:38 ET STEERus Identifies Misinterpretation Risk™ as a New Category of Business Risk in the Age of AI
increasingly difficult to stand out; especially those that have innovated or pivoted. According to STEERus founder and author Loralyn Mears, PhD, the problem may not be visibility at all. It may be Misinterpretation Risk™. This is the growing risk that people and AI systems misunderstand who
More news about: STEERus INC
Jul 14, 2026, 08:38 ET Autonomous Healthcare Receives FDA De Novo Marketing Authorization for Syncron-E™, the First Device in a New FDA Category of Ventilator Waveform Analysis Software
performance data."This FDA De Novo grant is a milestone years in the making and a defining moment for Autonomous Healthcare," said Behnood Gholami, PhD, Co-Founder and Chief Executive Officer of Autonomous Healthcare. "We took the harder path of creating a new device category because clinicians need
More news about: Autonomous Healthcare
Jul 14, 2026, 08:30 ET CENTURY LITHIUM ANNOUNCES CHANGE IN BOARD LEADERSHIP
centurylithium.com.ON BEHALF OF CENTURY LITHIUM CORP.WILLIAM WILLOUGHBY, PhD., PE President & Chief Executive Officer
More news about: Century Lithium Corp.
Jul 14, 2026, 07:50 ET Former Client and Three-Decade Data Sciences Leader John Reynders, PhD, Joins Rancho BioSciences Leadership on Board of Directors
Rancho BioSciences today announced the appointment of John Reynders, PhD, MBA, to its Board of Directors. In his board role, Dr. Reynders will bring strategic depth to Rancho's product direction and growth priorities, with
More news about: Rancho BioSciences
Jul 14, 2026, 05:00 ET Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care
and opens a new era in personalized treatment for patients living with Parkinson's disease and other neurological conditions." — Lorenzo Rossi, PhD, Co-Founder, CEO & CTO of Newronika.Conventional Deep Brain Stimulation delivers fixed stimulation, regardless of how a patient's brain state
More news about: Newronika
Jul 14, 2026, 05:00 ET Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care
and opens a new era in personalized treatment for patients living with Parkinson's disease and other neurological conditions." — Lorenzo Rossi, PhD, Co-Founder, CEO & CTO of Newronika.Conventional Deep Brain Stimulation delivers fixed stimulation, regardless of how a patient's brain state
More news about: Newronika
Jul 13, 2026, 19:03 ET ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
kind of scalable care model Alzheimer's will need as the field moves from single-drug treatment toward combination therapies," said Laura Nisenbaum, PhD, Interim Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF). "Making treatment more convenient and accessible matters because
More news about: Alzheimer's Drug Discovery Foundation
Jul 13, 2026, 13:00 ET What Is Your Clothing Trying to Tell You?
author Lisa Feldman Barrett, PhD, neuroscientist and NYU Dean Wendy Suzuki, PhD, futures designer Nick Foster, RDI, sleep psychologist Jade Wu, PhD, broadcaster and author Krista Tippett, journalist and author Eliot Stein, medical anthropologist and author Theresa MacPhail, PhD, poet, activist, and author
More news about: Unlikely Collaborators
Jul 13, 2026, 11:00 ET APTA, Hartford HealthCare Rehabilitation Network Launch Frailty Pilot to Inform Value-Based Payment Models with Real-World Data
HealthCare represents a significant step forward in transforming how we think about aging and care delivery," said APTA President Kyle Covington, PT, DPT, PhD. "By leveraging the unique role of physical therapists to identify risk earlier and intervene proactively, we have an opportunity to improve health outcomes
More news about: American Physical Therapy Association
Jul 13, 2026, 10:12 ET The Alzheimer's Drug Discovery Foundation and The Michael J. Fox Foundation Launch $5 Million Partnership to Target Key Co-Pathologies Driving Alzheimer's and Parkinson's
neurodegenerative diseases by their underlying biology and better understand how these pathologies occur across the disease spectrum," said Mark Frasier, PhD, Chief Scientist at The Michael J. Fox Foundation. "MJFF has a longstanding track record of enabling biomarker discovery in Parkinson's disease, and
More news about: Alzheimer's Drug Discovery Foundation
Jul 13, 2026, 09:05 ET RESEARCH ALLIANCE CORPORATION IV ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING
subject to customary closing conditions. The Company, sponsored by an affiliate of RA Capital Management, L.P., is led by CEO Matthew Hammond, PhD, MBA and CBO/COO Henry Stusnick. The Company is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition,
More news about: Research Alliance Corporation IV
Jul 13, 2026, 09:04 ET Status Labs Releases 2026 Edition of AI Reputation Management White Paper as ChatGPT Hits 2.5B Daily Queries
Authored by Will Kidder, PhD, Head of Content Operations at Status Labs, the 2026 edition updates the firm's 2025 analysis with new sections on AI agents and reasoning models and
More news about: Status Labs
Jul 13, 2026, 09:00 ET Spark Biomedical and Feinstein Institutes Publish First-in-Human Study Demonstrating Non-Invasive tAN® Technology Enhances Platelet Function
non-pharmacologic treatments for severe bleeding."This study marks an important milestone for bioelectronic medicine," said Navid Khodaparast, PhD, Chief Science Officer and Co-founder of Spark Biomedical. "For the first time, we have shown that Spark's core tAN® technology can modulate
More news about: Spark Biomedical
Jul 13, 2026, 09:00 ET Thomas Jefferson University to Establish Regional Medical College Campus in Lehigh Valley
and Delaware, and the continued growth of our academic and clinical programs, this is a time of tremendous opportunity," said Susan C. Aldridge, PhD, President, Thomas Jefferson University. "These initiatives reflect our commitment to address critical workforce needs while building sustainable
More news about: Thomas Jefferson University
Jul 13, 2026, 08:39 ET Chonnam National University Researchers Reveal Isoform-Specific HIF Signaling in Skeletal Muscles
erythropoietin (EPO). When the researchers selectively deleted EPO from muscle, the hematological abnormalities seen in PHD triple-knockout mice normalized, confirming that the PHD–HIF2α axis produces EPO from myofibers. "This indicates that skeletal muscle may represent an additional source of EPO
More news about: Chonnam National University
Jul 13, 2026, 08:30 ET Streamline Targeted LNP Development to Improve Preclinical Translation, Upcoming Webinar Hosted by Xtalks
Horhota, PhD; Nicholas Boylan, PhD, Senior Director, Scientific Services, Phosphorex; Syed Reza, MD-PhD, Licensing
More news about: Xtalks
Jul 13, 2026, 08:30 ET Reduce Recruitment Risk by Understanding Patient Decisions, Upcoming Webinar Hosted by Xtalks
shaped by normalcy, identity and disruption, and how these insights can support more patient-informed clinical development.Join Elena Rodgers, PhD, Associate Director, Patient Insights,
More news about: Xtalks